Neither did DCX/FF-treatment upregulate Cx43 in these cells (not shown), even though it has previously been shown to trigger an expansion of super-resistant and invasive prostate cancer cell lineages from CD44+ cells [28]. The gene discussed is CD44; the disease is prostate cancer.